Capricor Gains Phase 3 HOPE-3 Support for Deramiocel Ahead of August 2026 PDUFA Date

With a PDUFA date of August 22, 2026 now fixed on the calendar, Capricor Therapeutics' BLA for deramiocel has gained additional clinical weight from phase 3 HOPE-3 data presented at the 2026 American Society of Gene and Cell Therapy Annual Meeting, data that regulatory affairs and QA teams at biologics manufacturers should read carefully given the manufacturing complexity of cardiosphere-derived cell products under biologics licensure.

The HOPE-3 trial enrolled 106 boys and young men aged 10 and older with Duchenne muscular dystrophy (DMD), randomized to intravenous deramiocel or placebo every three months over 12 months. The study met its primary endpoint: a statistically significant 4.55% advantage over placebo in total Performance of Upper Limb (PUL 2.0) score (95% CI, 0.47–8.63; P =.029), with an 8.12% benefit at mid-level PUL function (95% CI, 2.12–14.11; P =.008).

Cardiac endpoints reinforced the skeletal findings. Deramiocel produced a statistically significant improvement in left ventricular ejection fraction, with an absolute treatment difference of approximately 2.4% versus placebo (P =.041). Among patients with evaluable gadolinium-enhanced cardiac MRI, myocardial fibrosis progression was reduced over 12 months, with a mean treatment difference of –3.00 affected cardiac segments (95% CI, –5.50 to –0.51; P =.022). Lead author Jonathon H. Soslow, MD, of Vanderbilt University Medical Center, described the results as achieving primary muscle function and secondary cardiac endpoints in a second randomized placebo-controlled study with a favorable safety profile.

The fibrosis data carry particular weight for the DMD population: cardiomyopathy is among the leading causes of mortality in this disease, driven by progressive fibrofatty replacement of cardiac tissue and declining ventricular function. Investigators noted these findings may represent the first clinical evidence that antifibrotic effects seen in preclinical mdx mouse models translate into measurable cardiac benefit in humans.

For regulatory and manufacturing teams, the biologics licensure pathway for an allogeneic, cardiosphere-derived cell therapy introduces distinct lot-release and process validation considerations not present in small-molecule or conventional biologic submissions. The BLA under FDA review incorporates data from both HOPE-3 and prior studies, and the agency's evaluation will encompass the full manufacturing control strategy alongside the clinical package.

The August 22, 2026 PDUFA date now serves as the near-term checkpoint against which Capricor's manufacturing readiness and the FDA's review of the biologics license application will converge.

Source: CGTlive via Capricor Therapeutics / ASGCT Annual Meeting presentation, May 18, 2026.